RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury
March 20, 2024 08:30 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), focused on the discovery and development of innovative and...
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
March 01, 2024 16:04 ET
|
NurExone Biologic Inc
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
Climate Change Challenge Creates Solutions for Vulnerable Populations
February 20, 2024 15:57 ET
|
Praxis Spinal Cord Institute
Vancouver, BC, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Praxis Spinal Cord Institute NEWS RELEASEFor Immediate Release February 20, 2024 Climate Change Challenge Creates Solutions for Vulnerable...
Wandercraft's self-balancing exoskeleton receives second FDA clearance in less than a year, now indicated for rehabilitation in patients with spinal cord injury
February 13, 2024 08:05 ET
|
Wandercraft
Wandercraft's self-balancing exoskeleton receives second FDA clearance in less than a year, now indicated for rehabilitation in patients with spinal cord injury This marks Wandercraft’s second FDA...
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant
February 02, 2024 16:05 ET
|
NurExone Biologic Inc
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant for its groundbreaking ExoPTEN product
NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration
November 29, 2023 08:30 ET
|
NurExone Biologic Inc
NurExone Biologic expands its portfolio of products to address spinal cord injuries & neuron regeneration in CNS indications
NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 24, 2023 08:30 ET
|
NurExone Biologic Inc
NurExone released a corporate update and reported financial results for the quarter ended September 30, 2023.
NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment
October 30, 2023 09:20 ET
|
NurExone Biologic Inc
NurExone Biologic Receive FDA Orphan-Drug Designation to its ExoPTEN Therapy for Acute Spinal Cord Injury Treatment
Appointment of Professor Teo Forcht Dagi to Scientific Advisory Board and Advisory Committee
October 19, 2023 08:30 ET
|
NurExone Biologic Inc
NurExone Biologic welcomes Prof. Teodoro Forcht Dagi, a renowned neurosurgeon and life science venture capitalist, to its Scientific Advisory Board.
ONWARD® Announces First-in-Human Implant of ARC-IM™ Stimulator with Brain-Computer Interface (BCI) to Restore Arm, Hand, and Finger Function after Spinal Cord Injury
September 27, 2023 01:30 ET
|
ONWARD Medical NV
Eindhoven, Sept. 27, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement,...